• search
CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
In vitro Biology Services

In vitro Biology Services

In vitro biology services at Aurigene are focused on running standard and highly specialized biochemical and cell based assays and providing expertise to support stand alone or integrated drug discovery programs.

Our in vitro biology team is highly skilled in wide range of therapeutic areas and target classes. De novo assay development for novel target classes or therapeutic indications, as well as assay customization, has added significant value to our Integrated Drug Discovery (IDD) projects. This has also resulted in successful compound progression and clinical candidate nomination.

Our offerings include screening and profiling services or platforms under different therapeutic areas and target classes. We have experience in target classes like GPCRs, ion channels, proteases, other hydrolytic enzymes, membrane receptors etc. Aurigene focuses and caters to a wide range of therapeutic areas like asthma and COPD, metabolic disorders, inflammation, oncology, immunology, stem cell biology, osteoporosis, angiogenesis, CNS, and pain. We also have experience in epigenetics and protein-protein Interaction targets. At Aurigene, we are continuously adding the services for advanced and emerging drug classes like PROTAC, Oligonucleotide, ADC and mRNA. We offer a complete set of bioassays for PROTAC discovery.

Speak to our experts

In vitro assay Development

  • Cell based assays: To understand the correlation of networks in a complex biological system, we can design custom cell-based assays that cater to every stage of drug development. We have a wide range of cell types which in combination with innovative technologies result in assays with improved translational success.
  • Biochemical assays: We have expertise in all standard biochemical assays and ability to customize specialized assays as per the requirements. We established novel biochemical assays without any literature precedence. This includes generation of critical tools and reagents, optimization, validation and screening. More than 50 assays are running at any point of time in various programs (IDD and Standard). For IDD programs, we have capability to support primary assays to drive and support Structure Activity Relationship (SAR). We have capability to undertake Functional, Mechanism of Action (MoA) and target engagement studies at the lead and optimized lead stage. Some biochemical assays are designed as per Structure Based Drug Design (SBDD) tools.
  • Mechanistic assays: Mechanistic assays are an important part of our in vitro service portfolio, as they provide further information about the cellular or molecular mechanism displayed by the study compound. All assays are with fluorescence or luminescence endpoints.
  • Screening: Medium to high throughput screening in different assay platforms, liquid handling platform for 384 well format.
  • Readout platforms: We offer diverse readout platforms such as Luminescence, Fluorescence (FRET, TR-FRET), Fluorescence Polarization (FP), AlphaLISA, AlphaScreen, Absorbance, UV to NIR, Flow cytometry, Western blot, qPCR etc.

In vitro assay Capability Range

  • Functional Assay
    • Cell Viability
    • Apoptosis
    • Invasion
    • Migration
    • Cell Senescence
    • Cell Cycle Analysis
    • Necroptosis Assay
    • Pyroptosis Assay
  • Specialized Assays
    • Target engagement assays via Nano-BRET/ CESTA
    • 3D cells co-culture
    • Spheroid culture
    • Organoid culture
    • Stem cell-derived functional cells – Hepatocytes, Cardiac etc.
  • Immunological Assays
    • Dendritic cell
    • T-cell cytotoxicity
    • Treg – Immune suppression
    • Immune cell profiling
    • Mixed lymphocyte
  • Biomarker Assay
    • Cytokine modulation
    • Target gene expression
    • Phosphorylation of signaling intermediates
    • Cytokine-induced transcription factor phosphorylation

Why Aurigene Pharmaceutical Services?

Complex and specialized assay development

High throughput expression system

Functional, Mechanism of Action (MoA) and Target Engagement Studies

Other Services

Virtual Tour

 

Contact Us

CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Resources

resourceMainImage

JUNE 28, 2022

Neoantigen Specific T cells For Cancer Immunotherapy

Neoantigen specific T cells for cellular cancer immunotherapy An effective anti-tumor immune response in human is marked by presence of T cells reactive against neoantigens. Neoantigens are HLA-bound unique peptides arise from tumor-specific somatic mutations. Neoantigens are highly immunogenic because they are not present in normal tissues and hence...

Read More
View All
resourceMainImage

Building successful long-term partnerships with CDMOs from early drug discovery through commercialization

Building successful long-term partnerships with CDMOs from early drug discovery through commercialization Maximizing efficiency in drug research, development, and manufacturing is crucial for turning new innovations into therapeutic and financial benefits. Over the past couple of decades, pharmaceutical companies have increasingly turned to contr...

Read More
View All
resourceMainImage

Carbohydrate

...

Read More
View All
resourceMainImage

Technology meets sustainability - How a complex API development process goes green

We are always looking for ways to enhance the sustainability of our products and services. Our team successfully developed a scalable manufacturing process for the API product of one of our Biotech clients using eco-friendly manufacturing technologies. Read the case study to learn more. ...

Read More

Alternate end-game strategies towards Nirmatrelvir synthesis: Defining a continuous flow process for the preparation of an anti-COVID drug

2023

Scalable alternate end-game strategies for the synthesis of the anti-COVID drug molecule Nirmatrelvir (1,PF-07321332) have been described. The first involves a direct synthesis of 1 via amidation of the carboxylic acid 7 (suitably activated as a mixed anhydride with either pivaloyl chloride or T3P) with the ...

Read More
View All
×

You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.

If you wish to continue to this external website, click Proceed.

ProceedBack